Login to Your Account

Other News To Note

Friday, March 4, 2011
Oxygen Biotherapeutics Inc., of Morrisville, N.C., received a $2.075-million, two-year grant from the U.S. Army to study its Oxycyte perfluorocarbon (PFC) emulsion as a therapeutic intervention to reduce brain damage in victims of traumatic brain injury. PFC emulsions interact with the reticuloendothelial system as part of the clearance mechanism and affect the number of circulating platelets. The preclinical studies supported by the Army grant will examine the effects of Oxycyte on the immune system, platelet function and distribution, as well as the safety and efficacy of platelet transfusion.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription